Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 +4.99%69 Gross Margin % is 20.47% as of Jun. 2026, which is 38% above its 10-year median of 14.88. GuruFocus rates BOM:531762 with a GF Score™ of 69/100 and a GF Value™ of ₹22.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 940 Drug Manufacturers companies, Unjha Formulations ranks worse than 89.47% on this metric.
The historical rank and industry rank for Unjha Formulations's Gross Margin % or its related term are showing as below:
BOM:531762'
s Gross Margin % Range Over the Past 10 Years
Min: 10.9 Med: 14.88 Max: 21.62
Current: 21.62
During the past 13 years, the highestGross Margin % of Unjha Formulations was 21.62%. The lowest was 10.90%. And the median was 14.88%.
BOM:531762's Gross Margin % is ranked worse than 89.47% of 940
companies
in the Drug Manufacturers industry
Industry Median: 48.515
vs BOM:531762: 21.62
Unjha Formulations had a gross margin of 20.47% for the quarter that ended in Jun. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Unjha Formulations was 2.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Unjha Formulations had a gross margin of 20.47% for the quarter that ended in Jun. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Unjha Formulations Gross Margin % Related Terms
Unjha Formulations Gross Margin % Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Unjha Formulations (BOM:531762) has a Gross Margin % of 20.47% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Unjha Formulations and its competitors. This is 38% above median its historical median of 14.88. Over the past decade, Unjha Formulations' Gross Margin % has ranged from 10.90 to 21.62. According to the industry distribution chart, Unjha Formulations ranks #841 out of 940 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Unjha Formulations' Gross Margin % too high?
Unjha Formulations' current Gross Margin % of 20.47% is 38% above median its 10-year median of 14.88. Over the past 10 years, this metric has ranged from a low of 10.90 to a high of 21.62. The Drug Manufacturers industry median Gross Margin % is 48.52. Unjha Formulations' value of 20.47% is 57.8% below this industry median. Based on the distribution chart, Unjha Formulations ranks #841 out of 940 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unjha Formulations has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #841 out of 940 companies for Gross Margin %. This places Unjha Formulations in the lower half of its industry. The industry median Gross Margin % is 48.52. Unjha Formulations' value of 20.47% is 57.8% below this benchmark. Historically, Unjha Formulations' own Gross Margin % has ranged from 10.90 to 21.62 over the past decade. While the company's 10-year median is 14.88 vs. the industry median of 48.52, Unjha Formulations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.52, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current Gross Margin % of 20.47% is 57.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current Gross Margin % is 20.47%, which is 38% above median its own 10-year median of 14.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹22.87, compared to a current price of ₹32.17 — trading 40.7% above its estimated fair value. The current Gross Margin % is 20.47%, which is 38% above median its 10-year median of 14.88 and 57.8% below the Drug Manufacturers industry median of 48.52. Unjha Formulations' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current Gross Margin % is 20.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹32.17 is trading 40.7% above its estimated GF Value™ of ₹22.87.
GuruFocus considers Unjha Formulations to be Significantly Overvalued.
Key valuation signals for BOM:531762:
Gross Margin %: 20.47% (38% above median its 10-year median of 14.88)
GF Value™: ₹22.87 vs. price of ₹32.17 (40.7% above fair value)
Industry Position: 57.8% below the Drug Manufacturers median (#841 of 940)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
69GF Score
Get the complete analysis for BOM:531762
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
